You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯康生物科技集團(00690.HK):國家藥監局批准博舒泰(阿卡波糖片)在中國上市
格隆匯 12-15 20:30

格隆匯12月15日丨聯康生物科技集團(00690.HK)發佈公告,集團博舒泰(阿卡波糖片)已於2020年11月10日獲得國家藥品監督管理局(NMPA)在中國上市批准。公司已通過GMP生產檢驗,獲准於2020年12月10日開始生產博舒泰。這些批准意味着公司有資格生產和推出新批准的仿製藥博舒泰,是公司在代謝疾病領域的又一個里程碑。

博舒泰(阿卡波糖片)是集團繼金因肽、金因舒、匹納普、博康泰之後上市的第五款產品。下一步,公司將專注於博舒泰的推出和成功商業化。由於製造成本領先是該產品成功的關鍵,公司已經與多個供應鏈戰略伙伴合作,儘可能降低博舒泰的生產成本。

阿卡波糖片在臨牀上主要用於降低糖耐量低減者及二型糖尿病人羣的餐後血糖,是《中國2型糖尿病防治指南(2017版)》權威推薦的一線用藥,已被列入國家基本藥物目錄及國家醫療保險目錄。阿卡波糖主要通過抑制澱粉酶來減少葡萄糖的吸收,尤其適合以碳水化合物為主食的亞洲人羣。根據國際糖尿病組織IDF數據,中國目前糖尿病羣體高達1.14億。隨着老齡化趨勢和診斷治療率提升,以及醫保支付政策對慢病用藥的重視增加,中國糖尿病用藥市場在未來十年還將持續穩健增長。

阿卡波糖是中國銷量最大的口服降糖藥;中國公立醫療機構終端銷售數據顯示,2018年阿卡波糖製劑產品中國國內市場終端銷售規模約84億元人民幣,近5年市場規模保持兩位數複合增長率;各種市場趨勢與數據顯示,阿卡波糖現在和未來都擁有一個需求強大的市場。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account